AstraZeneca plc, is a large Anglo-Swedish pharmaceutical company formed in April 1999 by the merger of Swedish Astra and British Zeneca. Zeneca was originally known as ICI Pharmaceuticals, before it was demerged in June 1993 from the British chemicals company, ICI.

Sales in 2003 totalled $18.8 billion, with a profit before tax of $4.2 billion. Total R&D spend was $3.5 billion. The corporate HQ is in London UK, the R&D HQ in S dert lje, Sweden. Key R&D centres are located in Alderley Park, near Macclesfield, UK, and Wilmington, Delaware, USA.

The current chief executive of AstraZeneca is Sir Tom McKillop.

	Results from FactBites:
	AstraZeneca - Wikipedia, the free encyclopedia (608 words) AstraZeneca develops, manufactures, and sells pharmaceuticals to treat disorders in the gastrointestinal, cardiac and vascular, neurological and psychiatric, infection, respiratory, pathological inflammation and oncology areas. AstraZeneca is the major sponsor for Breast Cancer Awareness Month which focuses on early detection and treatment[4]. The Board of AstraZeneca PLC announces the appointment of David R Brennan as Chief Executive with effect from 1 January 2006 upon the retirement at that time of Sir Tom McKillop. ASTRAZENECA PLC - Full Company Description | Reuters.com (1946 words) AstraZeneca PLC (AstraZeneca), incorporated on June 17, 1992, discovers, develops, manufactures and markets prescription pharmaceuticals for various areas of healthcare, including cardiovascular, gastrointestinal, neuroscience, oncology, respiratory and inflammation, and infection. AstraZeneca has a range of compounds in early development, and a total of 17 projects in Phase I, 15 projects in Phase II and 29 projects in Phase III development. AstraZeneca is focusing on developing approaches to treating GERD, IBD and functional gastrointestinal disorders (FGD), such as irritable bowel syndrome (IBS) and functional dyspepsia.
	More results at FactBites »